Nippon India Pharma Fund · Regular · Growth
NAV
₹569.4618
as of 29 Sept 2026
Expense Ratio
1.84%
AUM
₹8,513 Cr
Lumpsum returns (CAGR)
- 1Y
- +14.41%
- 3Y
- +17.34%
- 5Y
- +13.11%
- Since Inception
- +19.86%
SIP returns (XIRR)
- 1Y
- +16.28%
- 3Y
- +12.48%
- 5Y
- +16.25%
- Since Inception
- +18.43%
What history actually did — last 10 years (Sept 2016 – Sept 2026)
A ₹5,000 monthly SIP for the last 10 years (Sept 2016 – Sept 2026)
Real NAV backtest
A ₹5,000 monthly SIP would be worth ₹15,08,850 today — ₹6,00,000 invested, 17.6% XIRR.
₹6,00,000
Invested
₹15,08,850
Value today
17.6%
XIRR (p.a.)
A ₹1,00,000 lumpsum, the last 10 years (Sept 2016 – Sept 2026)
Real NAV backtest
₹1,00,000 invested 10 years ago would be ₹3,94,042 today (14.7% CAGR).
A regular withdrawal plan (SWP)
Real NAV backtest
A ₹10,00,000 corpus withdrawing ₹5,000/month since Sept 2016 would still hold ₹24,31,568.
Fund vs Benchmark (TRI)
Same SIP, benchmark total-return index
The same SIP would be worth ₹15,08,850 in this fund vs ₹11,24,556 in the benchmark — outperformance of ₹3,64,700.
Buying the worst day
Real NAV backtest
₹1,00,000 invested on the worst market day of the last 10 years (Sept 2016 – Sept 2026) (22 Mar 2020) would be ₹4,36,796 today (4.37×).
Historical simulation using actual published NAVs for the stated period. Past performance may or may not be sustained in the future. Not investment advice.
Risk Metrics
Trailing 1 year, annualised0.68
Sharpe Ratio
+0.12
Alpha
0.19
Beta
0.68
Sortino
12.06%
Std Dev
-10.24%
Max Drawdown
Performance Comparison
Sectoral allocation
as of 31 Aug 2026- Pharmaceuticals & Biotechnology73.98%
- Healthcare Services21.06%
- Retailing2.51%
- Healthcare Equipment & Supplies0.44%
Each sector links to the mutual funds most exposed to it.
Related reading
Thinking about Nippon India Pharma Fund · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Compare with Similar Funds
Fund Details
Available transactions
Portfolio holdings
- 1Sun Pharmaceutical Industries Limited12.37%
- 2Divi'S Laboratories Limited7.00%
- 3Lupin Limited6.43%
- 4Cipla Limited6.09%
- 5Apollo Hospitals Enterprise Limited5.15%
- 6Dr. Reddy'S Laboratories Limited4.93%
- 7Mankind Pharma Limited4.09%
- 8Sai Life Sciences Limited3.94%
- 9Ajanta Pharma Limited3.47%
- 10Glaxosmithkline Pharmaceuticals Limited3.31%
What this fund does
Nippon India Pharma Fund · Regular · Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
Nippon India Pharma Fund · Regular · Growth is a Sectoral / Thematic mutual fund offered by Nippon India Mutual Fund. The fund has been operational for over 22 years. It manages assets worth ₹8,513 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against BSE HEALTHCARE TRI. The current expense ratio is 1.84%.